DUBLIN--(BUSINESS WIRE)--The "North America Companion Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
According to this report the companion diagnostics market in North America is evaluated to attain a compound annual growth rate of 12.96% over the forecasting years 2022 to 2028. The United States and Canada shape the market in the region.
In Canada, several public and private initiatives are expected to widen the scope of the studied market, despite limited healthcare policy. For instance, the Alliance for Innovation in Molecular Diagnostics is working to improve the companion diagnostics innovation environment.
The initiatives also aim to decrease the lack of clarity on how decision-makers prioritize the CDx tests by highlighting the interprovincial regulations that deter CDx development and adoption.
Furthermore, HTA agencies, government agencies, and hospitals strive to promote CDx applications by providing reimbursements. Above all, innovative clinical trials, increased R&D investments, and healthcare plans are anticipated to fuel the Canadian companion diagnostics market's growth over the forecast period.
In the US, the rapid evolution of diagnostics technologies and investments are increasing the demand for advanced diagnostic testing. Moreover, the recent developments favoring comprehensive CDx tests to gain the necessary information to make therapeutic decisions are responsible for propelling the companion diagnostics market on a growth path.
Companies Mentioned
- Abbott Laboratories
- Almac Group
- Arup Laboratories
- Biocartis
- Biomerieux
- Danaher Corporation
- GE Healthcare
- Genomic Health
- Illumina Inc
- Myriad Genetics
- Qiagen
- Roche Diagnostics
- Sysmex Corporation
- Thermo Fisher Scientific
- Agilent
Key Topics Covered:
1. North America Companion Diagnostics Market - Summary
2. Industry Outlook
2.1. Impact of Covid-19 on the Companion Diagnostics Market
2.2. Key Insights
2.2.1. Commercial Success of Precision Medicine Treatment
2.2.2. Adoption of Predictive Biomarkers
2.2.3. Fusion of Computer Science and Biology
2.3. Porter'S Five Forces Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitutes
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Threat of Competitive Rivalry
2.4. Key Buying Impact Analysis
2.4.1. Cost
2.4.2. Availability
2.4.3. Sensitivity & Specificity
2.4.4. Efficacy
2.5. Market Attractiveness Index
2.6. Vendor Scorecard
2.7. Industry Components
2.8. Regulatory Framework
2.9. Key Market Strategies
2.9.1. Acquisitions
2.9.2. Product Launches
2.9.3. Contracts & Agreements
2.10. Market Drivers
2.10.1. Increase in Incidence of Medication Reactions
2.10.2. Increasing Prevalence of Cancer Cases and Fatalities
2.10.3. Rising Prevalence of Precision Medicines
2.11. Market Challenges
2.11.1. Weak Reimbursement Framework
2.11.2. Common Cases of Leakage in Oncology Companion Diagnostics
2.12. Market Opportunity
2.12.1. Ongoing Research and Investments in Next Generation Gene-Sequencing
3. North America Companion Diagnostics Market Outlook - by Mechanism
3.1. In-Situ Hybridization
3.2. Polymerase Chain Reaction
3.3. Immunohistochemistry
3.4. Next Generation Sequencing
3.5. Other Mechanisms
4. North America Companion Diagnostics Market Outlook - by Indicator
4.1. Oncology
4.2. Neurology
4.3. Infectious Diseases
4.4. Other Indicators
5. North America Companion Diagnostics Market Outlook - by Consumer
5.1. Pharmaceutical and Biopharmaceutical Companies
5.2. Reference Laboratories
5.3. Other Consumers
6. North America Companion Diagnostics Market Outlook - by Commodity
6.1. Assay Kits and Reagents
6.2. Software and Services
7. North America Companion Diagnostics Market - Country Outlook
7.1. United States
7.2. Canada
8. Competitive Landscape
9. Research Methodology & Scope
For more information about this report visit https://www.researchandmarkets.com/r/eliwuw
